Hisse Senetlerindeki Sıralama
#24756
Established in 2006 and headquartered in Tokyo, Japan, Solasia Pharma K.K. is... Established in 2006 and headquartered in Tokyo, Japan, Solasia Pharma K.K. is dedicated to the development and commercialization of oncology treatments throughout Japan and other parts of Asia. The company's marketed products include SP-03 (episil oral liquid), designed for the protection and relief of oral pain and inflammation (mucositis/stomatitis) resulting from cancer chemotherapy and radiation. Additionally, they offer SP-01 (Sancuso), a transdermal patch that delivers granisetron, an anti-emetic, into the bloodstream to manage chemotherapy-induced nausea and vomiting. Solasia Pharma's development pipeline features SP-02 (Darinaparsin), a mitochondrial-targeted agent that has successfully completed Phase III clinical trials for a range of hematologic and solid cancers. Also in Phase III clinical study is SP-05 (Arfolitixorin), which aims to bolster the anti-tumor effectiveness of fluorouracil in various cancers, including pancreatic, breast, stomach, and head and neck cancers. In its pre-clinical stage, SP-04 is being developed to address chemotherapy-induced peripheral neuropathy.
Ticaret Solasia Pharma K.K. (4597)
B piyasa değeri ile 4597 fiyatı
Piyasa Değeri Solasia Pharma K.K.(4597)
Piyasa Değeri: $57.00M
August 2026 itibarıyla Solasia Pharma K.K. şirketinin piyasa değeri $57.00M. Bu, verilerimize göre Solasia Pharma K.K. şirketini dünyanın en değerli 24756th. şirketi yapar. Piyasa değeri, halka açık bir şirketin tedavüldeki hisse senetlerinin toplam piyasa değeri olup, bir şirketin değerini ölçmek için yaygın olarak kullanılır.
Solasia Pharma K.K. piyasa değeri geçmişi (2017 - 2026)
En Popüler 5 stocks ile karşılaştırıldığında 4597
| 4597’in Fiyatı |
|
B Varlığı |
B’nin Piyasa Değeri |
Sonuçlar |
|
|
|
|
$5.257T
|
+9,222,689.99%
|
|
|
|
|
$4.599T
|
+8,067,923.66%
|
|
|
|
|
$4.107T
|
+7,204,622.15%
|
|
|
|
|
$3.577T
|
+6,275,948.87%
|
|
|
|
|
$2.807T
|
+4,925,127.16%
|
